The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022

In reply: On behalf of our co‐authors, we thank Islam and Seale for their interest in our article.1 We largely support the general sentiments of Islam and Seale.2 The seroprevalence survey that was the focus of our article was undertaken to support and guide the rapid public health response to the emergence of Japanese encephalitis virus (JEV) in New South Wales. The nature of a rapid public health response, which is focused on understanding enough to contain the risk in a short space of time, inherently limits the comprehensiveness of the epidemiological design.